AIDS Issues: Hearings Before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, Ninety-ninth Congress, First Session, on Research and Treatment for Acquired Immune Deficiency Syndrome, July 22, 1985; Protection of Confidentiality of Records of Research Subjects and Blood Donors, July 29, 1985; Cost of AIDS Care and who is Going to Pay, November 1, 1985, Volume 4U.S. Government Printing Office, 1985 - 357 pages |
From inside the book
Results 1-5 of 91
Page 7
... important to determine the incidence of new infections in order to monitor the current transmission patterns and to evaluate the impact of changes in behavior . To provide sound advice regarding personal protection , it is important to ...
... important to determine the incidence of new infections in order to monitor the current transmission patterns and to evaluate the impact of changes in behavior . To provide sound advice regarding personal protection , it is important to ...
Page 18
... important part of today's hearing that may be confusing . There are two types of AIDS treatments we are discussing today : AIDS taxes the immune system and makes the immune system itself sick . After this attack , the body then gives ...
... important part of today's hearing that may be confusing . There are two types of AIDS treatments we are discussing today : AIDS taxes the immune system and makes the immune system itself sick . After this attack , the body then gives ...
Page 19
... Important new developments show progress in this area . This technology , which is in its infancy , will develop into a methodology by which we will be able to rapidly screen large numbers of pa- tients for the AIDS virus and be able to ...
... Important new developments show progress in this area . This technology , which is in its infancy , will develop into a methodology by which we will be able to rapidly screen large numbers of pa- tients for the AIDS virus and be able to ...
Page 22
... important aspect of caring for the AIDS patient . A word about making drugs available for patients . In order for clinical testing to proceed with products intended for use in the treatment of AIDS , or any other condition , an IND ap ...
... important aspect of caring for the AIDS patient . A word about making drugs available for patients . In order for clinical testing to proceed with products intended for use in the treatment of AIDS , or any other condition , an IND ap ...
Page 27
... important new development . We hope that this technology , which is in its infancy , will develop into a method by which we will be able to rapidly screen large numbers of patients for the AIDS virus and be able to follow changes in the ...
... important new development . We hope that this technology , which is in its infancy , will develop into a method by which we will be able to rapidly screen large numbers of patients for the AIDS virus and be able to follow changes in the ...
Other editions - View all
Common terms and phrases
additional AIDS epidemic AIDS patients AIDS victims AIDS virus American antibody test antiviral agents Association Belle Glade blood and plasma blood banks blood or plasma blood products Blue Cross cells Chairman clinical confidentiality cost coverage DANNEMEYER diagnosis disability disclosure donate blood drug eligible ELISA employers estimated evaluation facilities factor IX factor VIII Federal funding Glades General Hospital health insurance hemophilia hospital HTLV-III antibody HTLV-III virus immune globulin increased risk individuals infected Kaposi's sarcoma LEHNHARD lymphadenopathy Medicaid Medicare million NIELSON Office of Biologics patients with AIDS percent persons plasma plasma collection plasma derivatives plasmapheresis positive potential present problem procedures programs protect Public Health Service questions reactive retrovirus risk groups SCHEUER screening sexual Source Plasma specific studies Subcommittee suramin Syndrome AIDS test results therapy tion transfusion trials viral WACHS WAXMAN Western blot York City
Popular passages
Page 171 - Records of the identity, diagnosis, prognosis, or treatment of any patient which are maintained in connection with the performance of any drug abuse prevention function...
Page 171 - ... conducted, regulated, or directly or indirectly assisted by any department or agency of the United States shall, except as provided in subsection (c), be confidential and be disclosed only for the purposes and under the circumstances expressly authorized under subsection (b) of this section.
Page 166 - An IRB may waive the requirement for the investigator to obtain a signed consent form for some or all subjects if it finds either: (1) That the only record linking the subject and the research would be the consent document and the principal risk would be potential harm resulting from a breach of confidentiality. Each subject will be asked whether the subject wants documentation linking the subject with...
Page 159 - Consistent with the recommendations of the American Red Cross, the American Association of Blood Banks, the Council of Community Blood Centers, the...
Page 165 - A disclosure of appropriate alternative procedures or courses of treatment, if any, that might be advantageous to the subject; (5) A statement describing the extent, if any, to which confidentiality of records identifying the subject will be maintained...
Page 166 - When appropriate, the research plan makes adequate provision for monitoring the data collected to ensure the safety of subjects. (7) When appropriate, there are adequate provisions to protect the privacy of subjects and to maintain the confidentiality of data.
Page 155 - DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville...
Page 178 - In addition, three major organizations dedicated to the development of high standards of donor protection and blood transfusion therapy — the American Association of Blood Banks, the American Red Cross, and the Council of Community Blood Centers...
Page 223 - The White House 1600 Pennsylvania Avenue NW Washington, DC 20500 Dear Mr. President: I am...
Page 150 - HTLV-III antibody should be offered to persons who may have been infected as a result of their contact with seropositive individuals (eg, sexual partners, persons with whom needles have been shared, infants born to seropositive mothers).